SUBSCRIBE
SUBSCRIBE
News   Drug Development

Hospitalization Not Cut by Gilead Sciences, Inc. Heart Drug-Study

April 5, 2011 | 
1 min read
NEW ORLEANS, April 4 (Reuters) - Gilead Sciences Inc's (GILD.O) heart drug Ranexa, while found to be effective in reducing chest pain in refractory angina patients, failed to cut hospitalizations in a small 100-patient study.
Clinical research Phase 2
Gilead Sciences, Inc.
MORE ON THIS TOPIC
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Drug Development
Beam one-ups Wave as both show promise of genetic editing for AATD
May 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Crawling manager or businessman tramped by big foot. Close-up view of feet on a tired and sweaty male worker's back . Flat vector illustration template.
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
May 20, 2026
 · 
2 min read
 · 
Tristan Manalac
sprint start in track and field in blurred motion
Rare diseases
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease
May 19, 2026
 · 
2 min read
 · 
Gabrielle Masson
Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .
Rare diseases
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop
May 19, 2026
 · 
2 min read
 · 
Tristan Manalac